131 The MICORDIS study Supplemental table 2. Dobutamine MCE-protocol Incremental infused doses 5 minutes of 10 µg/kg/min dobutamine 3 minutes of 20 µg/kg/min dobutamine 3 minutes of 30 µg/kg/min dobutamine 3 minutes of 40 µg/kg/min dobutamine Diagnostic endpoints Reaching maximal heart rate (i.e. ((220-age) x 0,85) Systolic blood pressure decrease greater than 20 mmHg Blood pressure above 220/120 mmHg Progressive symptoms of angina pectoris Dyspnea Dizziness Progressive arrhythmia Development of wall motility disorders in more than 1 wall segment as in myocardial ischemia Diagnostic relevant ST-T-segment changes Undesired effects Unbearable angina pectoris Ventricular tachycardia Bradycardia Myocardial ischemia Myocardial infarction Cardiac arrest Ventricular fibrillation Supplemental table 3. Myocardial response to hyperinsulinemia and dobutamine-induced stress ANOCA patients Healthy controls p-value Myocardial Blood Flow (ml/min/g) MBF, baseline 33.567 ±13.222 36.295 ±16.223 0.500 MBF, hyperinsulinemia 32.428 ±13.196 38.773 ±17.261 0.135 MBF, dobutamine-induced stress 29.932 ±16.459 43.322 ±18.461 0.008 MBF, ratio baseline-clamp, [IQR] 0.952 [0.724-1.179] 0.972 [0.688-1.362] 0.656 MBF, ratio baseline-dobutamine, [IQR] 0.867 [0.524-1.121] 1.077 [0.855-1.517] 0.030 Abbreviations: MBF: Myocardial Blood Volume; IQR: interquartile range 6
RkJQdWJsaXNoZXIy MTk4NDMw